Table 2.
Clinical, Therapy, and Laboratory Data in Patients with SLE
| Characteristic | Patients (N = 50) |
|---|---|
| Duration of SLE (years) | 9 ± 7 |
| Age of SLE diagnosis (years) | 30 ± 13 |
| Total SLEDAI (U) | 12 ± 10 |
| Non-Neuro-SLEDAI (U) | 8 ± 6 |
| Total SLICC (U) | 3 ± 2 |
| Non-Neuro-SLICC (U) | 2.5 ± 1.7 |
| Prednisone therapy (%) | 42 |
| Prednisone average dose (mg/d) | 8 ± 7 |
| Prednisone (years) | 7.2 ± 6.6 |
| Cyclophosphamide therapy (%) | 44 |
| Years of cyclophosphamide therapy (%) | 0.7 ± 0.9 |
| Methotrexate, azathioprine, mycophenalate, or retuximab (%) | 52 |
| Hydroxycloroquine or cloroquine therapy (%) | 62 |
| Warfarin, aspirin, or clopidogrel (%) | 38 |
| Positive DNA (%) | 44 |
| DNA titer (dilutions) | 66 ± 236 |
| ANA titer (dilutions) | 374 ± 455 |
| Smith antibody positive (%) | 30 |
| SSA antibody positive (%) | 38 |
| SSB antibody positive (%) | 12 |
| Ribonucleoprotein antibody positive (%) | 22 |
| Ribonucleoprotein titer (dilutions) | 4.7 ± 20 |
| C3 (mg/dl) | 99 ± 33 |
| C4 (mg/dl) | 20 ± 25 |
| CH50 (mg/dl) | 81 ± 37 |
| C-reactive protein (mg/dl) | 1.1 ± 1.5 |
| Erythrosedimentation rate (mm/hr) | 25.4 ± 25.2 |
| Antiphospholipid antibody positive (%) | 60 |
| IgM anticardiolipin antibody (IU) | 10 ± 15 |
| IgG anticardiolipin antibody (IU) | 13 ± 20 |
| IgA anticardiolipin antibody (IU) | 6 ± 12 |
| Beta 2 glycoprotein antibody positive (%) | 23 |
| Lupus-like inhibitor positive (%) | 33 |
Data presented as mean ± SD or %.
SLEDAI = SLE disease activity index; SLICC = SLE International Collaborating Clinics Damage Index; DNA = deoxyribonuclease antibody; ANA = antinuclear antibody.